A wealth of clinical evidence supports the safety of XIENCE™ Stent. It’s a decisive reason why interventional cardiologists (ICs) continue to be confident that the acute outcomes they observe in their patients will persist over the long term. XIENCE Skypoint™ Stent—with design improvements and a 48-mm stent option to treat long lesions—represents the latest generation among the XIENCE™ Stents.
XIENCE Skypoint™ Stent carries on the tradition of excellent XIENCE™ safety outcomes. The stent demonstrates consistency with optimal acute and early outcomes—in all types of patients and in complex lesions.2,3
|Types of Patients2,3||Types of Lesions2,3|
|Acute Myocardial Infarction (AMI)||Calcified Lesions|
The 99% device success rate was the lowest success rate noted, even among a range of patient types in multiple clinical trials.2
Early outcomes in AMI patients revealed that XIENCE™ Stent showed significant improvement 2 weeks after percutaneous coronary intervention (PCI). For example, during that timeframe the findings demonstrated:
XIENCE™ Stent also demonstrates safety among ST-elevation myocardial infarction (STEMI) patients, a subgroup of AMI patients. At 30 days, the rate of definite stent thrombosis (ST) with XIENCE™ Stent vs bare metal stents (BMS) was significantly lower: 0.4% vs 1.6%, p = 0.02.5
In other types of complex patients, early (30-day) outcomes reveal very low rates of definite ST. This includes patients with bifurcations, calcified lesions, and long lesions.
XIENCE™ Stent has significantly lower rates of acute and early ST than Synergy‡ and Resolute‡ DES.9,10
There is a 75% lower rate of acute (24-hour) definite ST with XIENCE™ Stent vs Synergy‡.9
There is an 88% lower rate of early (30-day) definite ST with XIENCE™ Stent vs Resolute‡.10
Platelet adhesion is a key factor in stent thrombosis, and the XIENCE™ Stent’s unique, durable fluoropolymer was created to ensure long-term protection from thrombosis.
Preclinical testing confirms that the XIENCE™ Stent exhibits the least platelet adhesion compared to other DES (p < 0.01). This factor protects patients from short-term complications.11
One-year subgroup analysis data from the STOPDAPT-2 trial showed excellent patient outcomes for high bleeding risk (HBR) patients using 1-month dual antiplatelet therapy (DAPT). Patients at high bleeding risk who followed a 1-month DAPT regimen had significantly lower event rates than those using a 12-month DAPT strategy.
Data from multiple studies show that XIENCE™ Stents deliver unparalleled patient outcomes which last far beyond the intervention. Extensive evidence of low definite ST rates is outlined below.
You are about to enter an Abbott country- or region-specific website.
Please be aware that the website you have requested is intended for the residents of a particular country or countries, as noted on that site. As a result, the site may contain information on pharmaceuticals, medical devices and other products or uses of those products that are not approved in other countries or regions
Do you wish to continue and enter this website?